Back to Trials
NCT07010692PHASE1, PHASE2Recruiting

Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment

Bruce Robinson, MD

Start Date

5/16/2025

Completion Date

6/1/2030

Summary

The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: biopsy confirmed squamous and/or basal cell carcinoma not previously treated by another method. Exclusion Criteria: * Cannot be pregnant at the time of treatment

Interventions

DRUG

Tirbanibulin ointment 1%

DEVICE

non-ablative fractional laser

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Keratinocyte CarcinomaBasal Cell CarcinomasSquamous Cell CarcinomaSkin Cancer

Locations

Bruce Robinson, MD

New York, New York 10022

United States